Citations (158)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Daniele Roberto Giacobbe, Silvia Corcione, Antonio Salsano, Filippo Del Puente, Simone Mornese Pinna, Francesco Giuseppe De Rosa, Malgorzata Mikulska, Francesco Santini & Claudio Viscoli. (2019) Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery. Expert Opinion on Pharmacotherapy 20:6, pages 751-772.
Read now
Read now
Matteo Bassetti & Elda Righi. (2016) Safety profiles of old and new antimicrobials for the treatment of MRSA infections. Expert Opinion on Drug Safety 15:4, pages 467-481.
Read now
Read now
Lorenzo Zaffiri, Jared Gardner & Luis H. Toledo-Pereyra. (2013) History of Antibiotics: From Fluoroquinolones to Daptomycin (Part 2). Journal of Investigative Surgery 26:4, pages 167-179.
Read now
Read now
Isabella Kanzler, Florian Weis & Andres Beiras-Fernandez. (2013) Current use of daptomycin in cardiac surgery and postoperative intensive care. Expert Review of Anti-infective Therapy 11:3, pages 309-320.
Read now
Read now
Aileen Rubio, Jeff Moore, Mustafa Varoglu, Mary Conrad, Min Chu, Walter Shaw & Jared A. Silverman. (2012) LC-MS/MS characterization of phospholipid content in daptomycin-susceptible and -resistant isolates of Staphylococcus aureus with mutations in mprF
. Molecular Membrane Biology 29:1, pages 1-8.
Read now
Read now
Hisham Ziglam. (2007) Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. Expert Opinion on Pharmacotherapy 8:14, pages 2279-2292.
Read now
Read now
Zeina A Kanafani & G Ralph Corey. (2007) Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Expert Review of Anti-infective Therapy 5:2, pages 177-184.
Read now
Read now
Javier Garau. (2006) Management of cSSTIs:the role of daptomycin. Current Medical Research and Opinion 22:11, pages 2079-2087.
Read now
Read now
Su Young Lee, Hong Wei Fan, Joseph L Kuti & David P Nicolau. (2006) Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opinion on Pharmacotherapy 7:10, pages 1381-1397.
Read now
Read now
D.R. Snydman, L.A. McDermott & N.V. Jacobus. (2005) Evaluation of In Vitro Interaction of Daptomycin with Gentamicin or Beta-lactam Antibiotics Against taphylococcus aureus and Enterococci by FIC Index and Timed-Kill Curves. Journal of Chemotherapy 17:6, pages 614-621.
Read now
Read now
Barry I Eisenstein. (2004) Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opinion on Investigational Drugs 13:9, pages 1159-1169.
Read now
Read now
Darren Abbanat, Mark Macielag & Karen Bush. (2003) Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opinion on Investigational Drugs 12:3, pages 379-399.
Read now
Read now
Neil Woodford. (2003) Novel agents for the treatment of resistant Gram-positive infections. Expert Opinion on Investigational Drugs 12:2, pages 117-137.
Read now
Read now
P Hopkins & S Sriskandan. (2002) Gram-positive bacterial infection in severe sepsis. Clinical Intensive Care 13:4, pages 147-160.
Read now
Read now
Paolo Tarsia, Francesco Blasi, Mario Cazzola, Roberto Cosentini & Piercarlo Braga. (2002) Therapies in development for community-acquired pneumonia. Expert Opinion on Investigational Drugs 11:4, pages 545-552.
Read now
Read now
P.C. Braga, D. Ricci & M. Dal Sasso. (2002) Daptomycin Morphostructural Damage in Bacillus cereus Visualized by Atomic Force Microscopy. Journal of Chemotherapy 14:4, pages 336-341.
Read now
Read now
Karen Bush, Mark Macielag & Joanna Clancy. (2000) ‘Superbugs’: new antibacterials in the pipeline. Emerging Drugs 5:4, pages 347-365.
Read now
Read now
Articles from other publishers (141)
Nihal Gören Sağlam, Nahdhoit Ahamada Rachid & Nihal Doğruöz Güngör. 2024. Bacterial Secondary Metabolites. Bacterial Secondary Metabolites
123
145
.
Anthony G. Pannullo, Brianne R. Zbylicki & Craig D. Ellermeier. (2023) Identification of DraRS in Clostridioides difficile, a Two-Component Regulatory System That Responds to Lipid II-Interacting Antibiotics. Journal of Bacteriology 205:10.
Crossref
Crossref
Hyochan Jang, Seong Yeol Choi & Robert J. Mitchell. (2023) Staphylococcus aureus Sensitivity to Membrane Disrupting Antibacterials Is Increased under Microgravity. Cells 12:14, pages 1907.
Crossref
Crossref
Mikio Ishii, Yuji Orito, Mari Shiomi, Rebecca E. Wrishko & Hiroyuki Yoshitsugu. (2023) Pharmacokinetics of intravenous daptomycin in Japanese pediatric patients: Pharmacokinetic comparisons supporting dosing recommendations in Japanese pediatric patients. Journal of Infection and Chemotherapy 29:6, pages 592-598.
Crossref
Crossref
Anthony G. Pannullo, Ziqiang Guan, Howard Goldfine & Craig D. Ellermeier. (2023) HexSDF Is Required for Synthesis of a Novel Glycolipid That Mediates Daptomycin and Bacitracin Resistance in C. difficile. mBio 14:2.
Crossref
Crossref
Venu M Ganipisetti, Natasha Dudiki, Anand Athavale, Pratyusha Bollimunta & Babu Sriram Maringanti. (2023) Daptomycin-Rifampin-Induced Rhabdomyolysis, Acute Renal Failure, and Hepatic Injury: A Case Report and Literature Review. Cureus.
Crossref
Crossref
Afifa, Nazim Hussain & Zulqarnain Baqar. 2023. Microbial Biomolecules. Microbial Biomolecules
375
403
.
Alexis C.R. Hoste, Sigrid Görgen & Philippe Jacques. 2023. Biosurfactants. Biosurfactants
203
247
.
Henry L. Stennett, Catherine R. Back & Paul R. Race. (2022) Derivation of a Precise and Consistent Timeline for Antibiotic Development. Antibiotics 11:9, pages 1237.
Crossref
Crossref
Lei Zhang, Tian Ai, Xiaoxi Tian, Chunmei Xu, Yonggui Wu, Zhongxu Yu & Shujuan Dai. (2022) Microwave-assisted preparation of Ag/Fe magnetic biochar from clivia leaves for adsorbing daptomycin antibiotics. Open Chemistry 20:1, pages 388-400.
Crossref
Crossref
Bismillah Mubeen, Aunza Nayab Ansar, Rabia Rasool, Inam Ullah, Syed Sarim Imam, Sultan Alshehri, Mohammed M. Ghoneim, Sami I. Alzarea, Muhammad Shahid Nadeem & Imran Kazmi. (2021) Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics. Antibiotics 10:12, pages 1473.
Crossref
Crossref
Lindsey N. Miller, Marea J. Blake, Eleanor F. Page, Hannah B. Castillo & Tessa R. Calhoun. (2021) Phosphate Ions Alter the Binding of Daptomycin to Living Bacterial Cell Surfaces. ACS Infectious Diseases 7:11, pages 3088-3095.
Crossref
Crossref
Timothy W. Jones, Ah Hyun Jun, Jessica L. Michal & William J. Olney. (2021) High-Dose Daptomycin and Clinical Applications. Annals of Pharmacotherapy 55:11, pages 1363-1378.
Crossref
Crossref
Pilar Blasco, Chunlei Zhang, Hoi Yee Chow, Guanhua Chen, Yongsheng Wu & Xuechen Li. (2021) An atomic perspective on improving daptomycin's activity. Biochimica et Biophysica Acta (BBA) - General Subjects 1865:8, pages 129918.
Crossref
Crossref
C. S. Brian Chia. (2021) A Review on the Metabolism of 25 Peptide Drugs. International Journal of Peptide Research and Therapeutics 27:2, pages 1397-1418.
Crossref
Crossref
Kenia Barrantes, Juan José Araya, Luz Chacón, Rolando Procupez‐Schtirbu, Fernanda Lugo, Gabriel Ibarra & Víctor H. Soto. 2021. Biosurfactants for a Sustainable Future. Biosurfactants for a Sustainable Future
245
268
.
Nicolas Gregoire, Alexia Chauzy, Julien Buyck, Blandine Rammaert, William Couet & Sandrine Marchand. (2020) Clinical Pharmacokinetics of Daptomycin. Clinical Pharmacokinetics 60:3, pages 271-281.
Crossref
Crossref
Debojyoti Mukherjee, Bipin Rooj & Ujjwal Mandal. 2021. Microbial Biosurfactants. Microbial Biosurfactants
271
291
.
John A. Karas, Glen P. Carter, Benjamin P. Howden, Adrianna M. Turner, Olivia K. A. Paulin, James D. Swarbrick, Mark. A. Baker, Jian Li & Tony Velkov. (2020) Structure–Activity Relationships of Daptomycin Lipopeptides. Journal of Medicinal Chemistry 63:22, pages 13266-13290.
Crossref
Crossref
Takuhei Yamamoto, Kousuke Sakamoto, Yukihiro Esaka & Bunji Uno. (2020) Highly Sensitive Fluorescence Detection of Daptomycin in Murine Samples through Derivatization with 2,3-Naphthalenedialdehyde. Analytical Sciences 36:10, pages 1285-1288.
Crossref
Crossref
Kanate Thitiananpakorn, Yoshifumi Aiba, Xin-Ee Tan, Shinya Watanabe, Kotaro Kiga, Yusuke Sato’o, Tanit Boonsiri, Feng-Yu Li, Teppei Sasahara, Yusuke Taki, Aa Haeruman Azam, Yuancheng Zhang & Longzhu Cui. (2020) Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA). Scientific Reports 10:1.
Crossref
Crossref
Maria Galletta, Tristan A. Reekie, Gayathri Nagalingam, Amy L. Bottomley, Elizabeth J. Harry, Michael Kassiou & James A. Triccas. (2020) Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. Antibiotics 9:8, pages 523.
Crossref
Crossref
Ioannis Anestopoulos, Despina-Evgenia Kiousi, Ariel Klavaris, Monica Maijo, Annabel Serpico, Alba Suarez, Guiomar Sanchez, Karina Salek, Stylliani A. Chasapi, Aikaterini A. Zompra, Alex Galanis, Georgios A. Spyroulias, Lourdes Gombau, Stephen R. Euston, Aglaia Pappa & Mihalis I. Panayiotidis. (2020) Marine-Derived Surface Active Agents: Health-Promoting Properties and Blue Biotechnology-Based Applications. Biomolecules 10:6, pages 885.
Crossref
Crossref
Avery Hunt & Donald R. Kirsch. (2020) Decision making in the pharmaceutical industry – A tale of three antibiotics. International Journal of Pharmaceutics 581, pages 119251.
Crossref
Crossref
Pradeep M.S.S, Saritha Yarava & Vishnuvardhan Rao K. (2020) Daptomycin susceptibility in enterococci isolated from urinary samples in a tertiary care hospital. IP International Journal of Medical Microbiology and Tropical Diseases 6:1, pages 48-53.
Crossref
Crossref
H. Shabeer Ali, K. Ajesh, K. V. Dileep, P. Prajosh & K. Sreejith. (2020) Structural characterization of Kannurin isoforms and evaluation of the role of β-hydroxy fatty acid tail length in functional specificity. Scientific Reports 10:1.
Crossref
Crossref
Caroline A. Davis & Elisabeth M.-L. Janssen. (2020) Environmental fate processes of antimicrobial peptides daptomycin, bacitracins, and polymyxins. Environment International 134, pages 105271.
Crossref
Crossref
Shinichi Watanabe, Yukinobu Kawakami, Hiroshi Kimura, Shinobu Murakami, Hitoshi Miyamoto, Shingo Takatori, Koichiro Suemori, Mamoru Tanaka, Akihiro Tanaka, Keiko Tanaka, Hisamichi Tauchi, Jun Maki, Hiroaki Araki & Takumi Yamaguchi. (2019) Association between daptomycin susceptibility and teicoplanin resistance in Staphylococcus epidermidis. Scientific Reports 9:1.
Crossref
Crossref
Alessandro Russo, Maddalena Peghin, Filippo Givone, Martina Ingani, Elena Graziano & Matteo Bassetti. (2019) Daptomycin-containing regimens for treatment of Gram-positive endocarditis. International Journal of Antimicrobial Agents 54:4, pages 423-434.
Crossref
Crossref
Izumo Kanesaka, Shingo Fujisaki, Yoshifumi Aiba, Shinya Watanabe, Takashi Mikawa, Akiko Kanayama Katsuse, Hiroshi Takahashi, Longzhu Cui & Intetsu Kobayashi. (2019) Characterization of compensatory mutations associated with restoration of daptomycin-susceptibility in daptomycin non-susceptible methicillin-resistant Staphylococcus aureus and the role mprF mutations. Journal of Infection and Chemotherapy 25:1, pages 1-5.
Crossref
Crossref
Ryan K Dare, Chad Tewell, Bryan Harris, Patty W Wright, Sara L Van Driest, Eric Farber-Eger, George E Nelson & Thomas R Talbot. (2018) Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy. Clinical Infectious Diseases 67:9, pages 1356-1363.
Crossref
Crossref
Nicolas Grégoire, Sandrine Marchand, Martine Ferrandière, Sigismond Lasocki, Philippe Seguin, Mickaël Vourc’h, Mathilde Barbaz, Thomas Gaillard, Yoann Launey, Karim Asehnoune, William Couet & Olivier Mimoz. (2018) Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. Journal of Antimicrobial Chemotherapy.
Crossref
Crossref
Brianne Zapata, Danya N. Alvarez, Sabrina Farah, Cristina Garcia-de-la-Maria, Jose M. Miro, George Sakoulas, Arnold S. Bayer & Nagendra N. Mishra. (2018) Prevention of High-Level Daptomycin-Resistance Emergence In Vitro in Streptococcus mitis-oralis by Using Combination Antimicrobial Strategies. Current Microbiology 75:8, pages 1062-1067.
Crossref
Crossref
Francisco Arnaiz de las Revillas, Marta Fernandez-Sampedro, Ana María Arnaiz-García, Manuel Gutierrez-Cuadra, Carlos Armiñanzas, Ivana Pulitani, Alejandro Ponton, Valentin Tascon, Ivan García & María Carmen Fariñas. (2018) Daptomycin treatment in Gram-positive vascular graft infections. International Journal of Infectious Diseases 68, pages 69-73.
Crossref
Crossref
Pooja Bhardwaj, Amrita Hans, Kinnari Ruikar, Ziqiang Guan & Kelli L. Palmer. (2018) Reduced Chlorhexidine and Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium after Serial Chlorhexidine Exposure. Antimicrobial Agents and Chemotherapy 62:1.
Crossref
Crossref
Alena Janda & Mather R.D. Jogendra. (2018) A case report and literature review of daptomycin-induced liver injury. IDCases 14, pages e00452.
Crossref
Crossref
?ngel Dom?nguez, Elisa Mu?oz, M. Carmen L?pez, Miguel Cordero, Jos? Pedro Mart?nez & Miguel Vi?as. (2017) Transcriptomics as a tool to discover new antibacterial targets. Biotechnology Letters 39:6, pages 819-828.
Crossref
Crossref
Constantina Kourmentza, Filomena Freitas, Vitor Alves & Maria A. M. Reis. 2017. Microbial Applications Vol.1. Microbial Applications Vol.1
29
77
.
Fred C. Tenover. 2017. Antimicrobial Drug Resistance. Antimicrobial Drug Resistance
1347
1357
.
Michael P. Gotsbacher, Sungmin Cho, Ho Jeong Kwon & Peter Karuso. (2017) Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans. Proteome Science 15:1.
Crossref
Crossref
Oscar Cirioni, Oriana Simonetti, Elisa Pierpaoli, Alessandra Barucca, Roberto Ghiselli, Fiorenza Orlando, Maria Pelloni, Maria Michela Cappelletti Trombettoni, Mario Guerrieri, Annamaria Offidani, Andrea Giacometti & Mauro Provinciali. (2016) Colistin enhances therapeutic efficacy of daptomycin or teicoplanin in a murine model of multiresistant Acinetobacter baumannii sepsis. Diagnostic Microbiology and Infectious Disease 86:4, pages 392-398.
Crossref
Crossref
Antonio D’Avolio, Debora Pensi, Lorena Baietto, Giovanni Pacini, Giovanni Di Perri & Francesco Giuseppe De Rosa. (2016) Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients. Drugs 76:12, pages 1161-1174.
Crossref
Crossref
Herbert Gbejuade, Bronwen Warner & James Murray. (2016) Daptomycin-loaded static cement spacer: salvage for a failed first-stage revision of a total knee replacement with vancomycin resistance. Current Orthopaedic Practice 27:3, pages 339-342.
Crossref
Crossref
Danyelle Santos, Raquel Rufino, Juliana Luna, Valdemir Santos & Leonie Sarubbo. (2016) Biosurfactants: Multifunctional Biomolecules of the 21st Century. International Journal of Molecular Sciences 17:3, pages 401.
Crossref
Crossref
Peng-Hui Yuan, Ri-Cheng Zhou, Xuepeng Chen, Shuai Luo, Feng Wang, Xu-Ming Mao & Yong-Quan Li. (2016) DepR1, a TetR Family Transcriptional Regulator, Positively Regulates Daptomycin Production in an Industrial Producer, Streptomyces roseosporus SW0702. Applied and Environmental Microbiology 82:6, pages 1898-1905.
Crossref
Crossref
Izumo KANESAKA, Akiko KANAYAMA, Ritsuko SHISHIDO, Utsuki UCHINO, Makoto NAGASHIMA, Shingo FUJISAKI & Intetsu KOBAYASHI. (2016) Decreasing Susceptibility of MRSA to Daptomycin During the Course of TreatmentDaptomycin 投与後に分離された同薬低感受性Methicillin-resistant <i>Staphylococcus aureus </i>の検討. Kansenshogaku Zasshi 90:4, pages 493-498.
Crossref
Crossref
Ikuo Aoki, Kensuke Ishikawa, Akira Wakana, Masako Aso & Tomoko Yoshinari. (2015) Evaluation of the safety, tolerability, and pharmacokinetics of a single bolus injection of daptomycin in healthy Japanese subjects. Journal of Infection and Chemotherapy 21:3, pages 170-175.
Crossref
Crossref
Letizia Fracchia, Jareer J. Banat, Massimo Cavallo, Chiara Ceresa & Ibrahim M. Banat. (2015) Potential therapeutic applications of microbial surface-active compounds. AIMS Bioengineering 2:3, pages 144-162.
Crossref
Crossref
Letizia Fracchia, Chiara Ceresa, Andrea Franzetti, Massimo Cavallo, Isabella Gandolfi, Jonathan Van Hamme, Panagiotis Gkorezis, Roger Marchant & Ibrahim Banat. 2014. Biosurfactants. Biosurfactants
245
268
.
Jordan R. Smith, Kimberly C. Claeys, Katie E. Barber & Michael J. Rybak. (2014) High-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It. Current Infectious Disease Reports 16:10.
Crossref
Crossref
John S. Bradley, David Benziger, Paula Bokesch & Richard Jacobs. (2014) Single-dose Pharmacokinetics of Daptomycin in Pediatric Patients 3–24 Months of Age. Pediatric Infectious Disease Journal 33:9, pages 936-939.
Crossref
Crossref
Yu-hua Xing, Wei Wang, Su-qin Dai, Ti-yan Liu, Jun-jie Tan, Guo-long Qu, Yu-xia Li, Yan Ling, Gang Liu, Xue-qi Fu & Hui-peng Chen. (2013) Daptomycin exerts rapid bactericidal activity against Bacillus anthracis without disrupting membrane integrity. Acta Pharmacologica Sinica 35:2, pages 211-218.
Crossref
Crossref
Tatiana Barichello, João Carlos Nepomuceno Gonçalves, Jaqueline S Generoso, Graziele L Milioli, Cintia Silvestre, Caroline S Costa, Jaqueline da Rosa Coelho, Clarissa M Comim & João Quevedo. (2013) Attenuation of cognitive impairment by the nonbacteriolytic antibiotic daptomycin in Wistar rats submitted to pneumococcal meningitis. BMC Neuroscience 14:1.
Crossref
Crossref
Hilda Tiricz, Attila Szűcs, Attila Farkas, Bernadett Pap, Rui M. Lima, Gergely Maróti, Éva Kondorosi & Attila Kereszt. (2013) Antimicrobial Nodule-Specific Cysteine-Rich Peptides Induce Membrane Depolarization-Associated Changes in the Transcriptome of Sinorhizobium meliloti. Applied and Environmental Microbiology 79:21, pages 6737-6746.
Crossref
Crossref
Nina Bionda, Jean-Philippe Pitteloud & Predrag Cudic. (2013) Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria. Future Medicinal Chemistry 5:11, pages 1311-1330.
Crossref
Crossref
Kheeldass Jugun, Pierre Vaudaux, Jorge Garbino, Leonardo Pagani, Pierre Hoffmeyer, Daniel Lew & Ilker U?kay. (2013) The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections. International Orthopaedics 37:7, pages 1375-1380.
Crossref
Crossref
R. Estes, J. Theusch, A. Beck, D. Pitrak & Kathleen M. Mullane. (2013) Activity of Daptomycin with or without 25 Percent Ethanol Compared to Combinations of Minocycline, EDTA, and 25 Percent Ethanol against Methicillin-Resistant Staphylococcus aureus Isolates Embedded in Biofilm. Antimicrobial Agents and Chemotherapy 57:4, pages 1998-2000.
Crossref
Crossref
Santi M. Mandal, Aulus E.A.D. Barbosa & Octavio L. Franco. (2013) Lipopeptides in microbial infection control: Scope and reality for industry. Biotechnology Advances 31:2, pages 338-345.
Crossref
Crossref
TianHua Zhang, Jawad K. Muraih, Evan Mintzer, Nasim Tishbi, Celine Desert, Jared Silverman, Scott Taylor & Michael Palmer. (2013) Mutual inhibition through hybrid oligomer formation of daptomycin and the semisynthetic lipopeptide antibiotic CB-182,462. Biochimica et Biophysica Acta (BBA) - Biomembranes 1828:2, pages 302-308.
Crossref
Crossref
Milya Davlieva, Wanna Zhang, Cesar A. Arias & Yousif Shamoo. (2013) Biochemical Characterization of Cardiolipin Synthase Mutations Associated with Daptomycin Resistance in Enterococci. Antimicrobial Agents and Chemotherapy 57:1, pages 289-296.
Crossref
Crossref
Jingxin Wang, Ryan Hudson & Herman O Sintim. (2012) Inhibitors of fatty acid synthesis in prokaryotes and eukaryotes as anti-infective, anticancer and anti-obesity drugs. Future Medicinal Chemistry 4:9, pages 1113-1151.
Crossref
Crossref
J. M. Wenisch, B. Meyer, V. Fuhrmann, K. Saria, C. Zuba, P. Dittrich & F. Thalhammer. (2011) Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. Journal of Antimicrobial Chemotherapy 67:4, pages 977-983.
Crossref
Crossref
Jawad K. Muraih, Jesse Harris, Scott D. Taylor & Michael Palmer. (2012) Characterization of daptomycin oligomerization with perylene excimer fluorescence: Stoichiometric binding of phosphatidylglycerol triggers oligomer formation. Biochimica et Biophysica Acta (BBA) - Biomembranes 1818:3, pages 673-678.
Crossref
Crossref
John B. Bossaer & Paul O. Lewis. (2011) Antibiotic Use in Home Health. Home Health Care Management & Practice 24:1, pages 50-55.
Crossref
Crossref
Anthony M. Nicasio, Jürgen B. Bulitta, Thomas P. Lodise, Rebecca E. D'Hondt, Robert Kulawy, Arnold Louie & George L. Drusano. (2012) Evaluation of Once-Daily Vancomycin against Methicillin-Resistant Staphylococcus aureus in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy 56:2, pages 682-686.
Crossref
Crossref
Jawad K. Muraih, Andre Pearson, Jared Silverman & Michael Palmer. (2011) Oligomerization of daptomycin on membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes 1808:4, pages 1154-1160.
Crossref
Crossref
Maryann Mikhail & Jeffrey M. Weinberg. 2011. Emergency Dermatology. Emergency Dermatology
18
33
.
Aileen Rubio, Mary Conrad, Robert J. Haselbeck, Kedar G. C., Vickie Brown-Driver, John Finn & Jared A. Silverman. (2011)
Regulation of
mprF
by Antisense RNA Restores Daptomycin Susceptibility to Daptomycin-Resistant Isolates of
Staphylococcus aureus
. Antimicrobial Agents and Chemotherapy 55:1, pages 364-367.
Crossref
Crossref
Longzhu Cui, Taisuke Isii, Minoru Fukuda, Tomonori Ochiai, Hui-min Neoh, Ilana Lopes Baratella da Cunha Camargo, Yukiko Watanabe, Mitsutaka Shoji, Tomomi Hishinuma & Keiichi Hiramatsu. (2010)
An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and Vancomycin in
Staphylococcus aureus
. Antimicrobial Agents and Chemotherapy 54:12, pages 5222-5233.
Crossref
Crossref
Francesco Scaglione. (2010) Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia. International Journal of Antimicrobial Agents 36, pages S33-S39.
Crossref
Crossref
Lee Rogers, Nicholas Bevilacqua & David Armstrong. 2010. MRSA, Second Edition. MRSA, Second Edition
78
96
.
N. N. Salama, J. H. Segal, M. D. Churchwell, J. H. Patel, L. Gao, M. Heung & B. A. Mueller. (2009) Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrology Dialysis Transplantation 25:4, pages 1279-1284.
Crossref
Crossref
Stefanie Henken, Jennifer Bohling, Jens Martens-Lobenhoffer, James C. Paton, A. David Ogunniyi, David E. Briles, Vyvyan C. Salisbury, Dirk Wedekind, Stefanie M. Bode-Böger, Thomas Welsh, Franz C. Bange, Tobias Welte & Ulrich A. Maus. (2010)
Efficacy Profiles of Daptomycin for Treatment of Invasive and Noninvasive Pulmonary Infections with
Streptococcus pneumoniae
. Antimicrobial Agents and Chemotherapy 54:2, pages 707-717.
Crossref
Crossref
Lorena Baietto, Antonio D’Avolio, Francesco Giuseppe De Rosa, Silvia Garazzino, Marianna Michelazzo, Giusi Ventimiglia, Marco Siccardi, Marco Simiele, Mauro Sciandra & Giovanni Di Perri. (2009) Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Analytical and Bioanalytical Chemistry 396:2, pages 791-798.
Crossref
Crossref
Dirk M. Elston. (2009) Update on Cutaneous Manifestations of Infectious Diseases. Medical Clinics of North America 93:6, pages 1283-1290.
Crossref
Crossref
Dennis A. K. Rice & Luke Mendez-Vigo. (2008) Daptomycin in bone and joint infections: a review of the literature. Archives of Orthopaedic and Trauma Surgery 129:11, pages 1495-1504.
Crossref
Crossref
Arnold L. Demain. (2009) Antibiotics: Natural products essential to human health. Medicinal Research Reviews 29:6, pages 821-842.
Crossref
Crossref
Richard H. Baltz. 2009. Natural Product Chemistry for Drug Discovery. Natural Product Chemistry for Drug Discovery
395
409
.
Addison K. MayRenae E. StaffordEileen M. BulgerDaithi HeffernanOscar GuillamondeguiGrant BochicchioSoumitra R. Eachempati. (2009) Treatment of Complicated Skin and Soft Tissue Infections. Surgical Infections 10:5, pages 467-499.
Crossref
Crossref
Noha N. Salama, Jonathan H. Segal, Mariann D. Churchwell, Jignesh H. Patel, Lihong Gao, Michael Heung & Bruce A. Mueller. (2009) Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology 4:7, pages 1190-1194.
Crossref
Crossref
Pamela A Moise, Ellie Hershberger, Maria I Amodio-Groton & Kenneth C Lamp. (2009) Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy. Annals of Pharmacotherapy 43:7-8, pages 1211-1219.
Crossref
Crossref
Nagendra N. Mishra, Soo-Jin Yang, Ayumi Sawa, Aileen Rubio, Cynthia C. Nast, Michael R. Yeaman & Arnold S. Bayer. (2009)
Analysis of Cell Membrane Characteristics of In Vitro-Selected Daptomycin-Resistant Strains of Methicillin-Resistant
Staphylococcus aureus
. Antimicrobial Agents and Chemotherapy 53:6, pages 2312-2318.
Crossref
Crossref
F. K. Gould, R. Brindle, P. R. Chadwick, A. P. Fraise, S. Hill, D. Nathwani, G. L. Ridgway, M. J. Spry & R. E. Warren. (2009) Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. Journal of Antimicrobial Chemotherapy 63:5, pages 849-861.
Crossref
Crossref
Fred C. Tenover. 2009. Antimicrobial Drug Resistance. Antimicrobial Drug Resistance
1151
1159
.
Mark D. Johnson & Catherine F. Decker. (2008) Antimicrobial Agents in Treatment of MRSA Infections. Disease-a-Month 54:12, pages 793-800.
Crossref
Crossref
P. M. Hawkey. (2008) Pre-clinical experience with daptomycin. Journal of Antimicrobial Chemotherapy 62:Supplement 3, pages iii7-iii14.
Crossref
Crossref
David Jung, Jon Paul Powers, Suzana K. Straus & Robert E.W. Hancock. (2008) Lipid-specific binding of the calcium-dependent antibiotic daptomycin leads to changes in lipid polymorphism of model membranes. Chemistry and Physics of Lipids 154:2, pages 120-128.
Crossref
Crossref
Arunachalam Muthaiyan, Jared A. Silverman, Radheshyam K. Jayaswal & Brian J. Wilkinson. (2008)
Transcriptional Profiling Reveals that Daptomycin Induces the
Staphylococcus aureus
Cell Wall Stress Stimulon and Genes Responsive to Membrane Depolarization
. Antimicrobial Agents and Chemotherapy 52:3, pages 980-990.
Crossref
Crossref
Andrew Udy, Jason Roberts, Robert Boots & Jeffrey Lipman. 2008. Sepsis. Sepsis
97
136
.
Lee Rogers, Nicholas Bevilacqua & David Armstrong. 2007. MRSA. MRSA
71
88
.
Arnold L. Demain. (2007) REVIEWS: The business of biotechnology. Industrial Biotechnology 3:3, pages 269-283.
Crossref
Crossref
Carl Fossaceca. (2007) Outcomes analysis of daptomycin use in a community hospital. Advances in Therapy 24:3, pages 517-528.
Crossref
Crossref
Dirk M. Elston. (2007) Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus: Management Principles and Selection of Antibiotic Therapy. Dermatologic Clinics 25:2, pages 157-164.
Crossref
Crossref
John S. Steinberg, Paul J. Kim & Mark R. Abbruzzese. (2007) An Infectious Disease Update on Antibiotics: Emerging Resistance. Clinics in Podiatric Medicine and Surgery 24:2, pages 285-309.
Crossref
Crossref
Dirk M. Elston. (2007) Community-acquired methicillin-resistant Staphylococcus aureus. Journal of the American Academy of Dermatology 56:1, pages 1-16.
Crossref
Crossref
J. A. Roberts & J. Lipman. 2007. Infectious Diseases in Critical Care. Infectious Diseases in Critical Care
122
146
.
Heinz J Schaad, Manuela Bento, Daniel P Lew & Pierre Vaudaux. (2006) Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection. BMC Infectious Diseases 6:1.
Crossref
Crossref
Mandy Wootton, Alasdair P. MacGowan & Timothy R. Walsh. (2006)
Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate
Staphylococcus aureus
(GISA) and Heterogeneous GISA Isolates
. Antimicrobial Agents and Chemotherapy 50:12, pages 4195-4197.
Crossref
Crossref
Burke A. Cunha. (2006) Antimicrobial Therapy of Multidrug-Resistant Streptococcus pneumoniae, Vancomycin-Resistant Enterococci, and Methicillin-Resistant Staphylococcus aureus. Medical Clinics of North America 90:6, pages 1165-1182.
Crossref
Crossref
Alan Johnson. (2006) Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Future Microbiology 1:3, pages 255-265.
Crossref
Crossref
George Sakoulas, Jeff Alder, Claudie Thauvin-Eliopoulos, Robert C. MoelleringJr.Jr. & George M. Eliopoulos. (2006)
Induction of Daptomycin Heterogeneous Susceptibility in
Staphylococcus aureus
by Exposure to Vancomycin
. Antimicrobial Agents and Chemotherapy 50:4, pages 1581-1585.
Crossref
Crossref
Longzhu Cui, Eiji Tominaga, Hui-min Neoh & Keiichi Hiramatsu. (2006)
Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate
Staphylococcus aureus
. Antimicrobial Agents and Chemotherapy 50:3, pages 1079-1082.
Crossref
Crossref
Amir Kazory, Kourosh Dibadj & I. David Weiner. (2006) Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. Journal of Antimicrobial Chemotherapy 57:3, pages 578-579.
Crossref
Crossref
Burke A. Cunha, Naveed Hamid, Heather Kessler & Subha Parchuri. (2005) Daptomycin cure after cefazolin treatment failure of Methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) line. Heart & Lung 34:6, pages 442-447.
Crossref
Crossref
Christopher A. Schriever, Cristina FernándezKeith A. Rodvold & Larry H. Danziger. (2005) Daptomycin: A novel cyclic lipopeptide antimicrobial. American Journal of Health-System Pharmacy 62:11, pages 1145-1158.
Crossref
Crossref
Vivian Miao, Marie-Françoise Coëffet-LeGal, Paul Brian, Renee Brost, Julia Penn, Andrew Whiting, Steven Martin, Robert Ford, Ian Parr, Mario Bouchard, Christopher J. Silva, Stephen K. Wrigley & Richard H. Baltz. (2005) Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry. Microbiology 151:5, pages 1507-1523.
Crossref
Crossref
Kelly Echevarria, Paromita Datta, Jose Cadena & James S. LewisIIII. (2005) Severe myopathy and possible hepatotoxicity related to daptomycin. Journal of Antimicrobial Chemotherapy 55:4, pages 599-600.
Crossref
Crossref
Ravindran A. Padmanabhan, Steven P. LaRosa & Kenneth J. Tomecki. (2005) What's New in Antibiotics?. Dermatologic Clinics 23:2, pages 301-312.
Crossref
Crossref
Richard H. Baltz, Vivian Miao & Stephen K. Wrigley. (2005) Natural products to drugs: daptomycin and related lipopeptide antibiotics. Natural Product Reports 22:6, pages 717.
Crossref
Crossref
Arnold L. Demain & Lixin Zhang. 2005. Natural Products. Natural Products
3
29
.
Kenneth S. Rotondi & Lila M. Gierasch. (2005) A well-defined amphipathic conformation for the calcium-free cyclic lipopeptide antibiotic, daptomycin, in aqueous solution. Biopolymers 80:2-3, pages 374-385.
Crossref
Crossref
F.B. Oleson, C.L. Berman & A.P. Li. (2004) An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chemico-Biological Interactions 150:2, pages 137-147.
Crossref
Crossref
Jan-Ji Lai & Stephanie K Brodeur. (2004) Physical and Chemical Compatibility of Daptomycin with Nine Medications. Annals of Pharmacotherapy 38:10, pages 1612-1616.
Crossref
Crossref
Brian S. Burleson, David J. Ritchie, Scott T. Micek & W. Michael Dunne. (2012)
Enterococcus faecalis
Resistant to Linezolid: Case Series and Review of the Literature
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 24:9, pages 1225-1231.
Crossref
Crossref
F.M.E. Wagenlehner & K.G. Naber. (2004) New drugs for Gram-positive uropathogens. International Journal of Antimicrobial Agents 24, pages 39-43.
Crossref
Crossref
Karen M Wesson, Daniel S Lerner, Nanette B Silverberg & Jeffrey M Weinberg. (2004) Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Disease-a-Month 50:7, pages 395-406.
Crossref
Crossref
David Jung, Annett Rozek, Mark Okon & Robert E.W Hancock. (2004) Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin. Chemistry & Biology 11:7, pages 949-957.
Crossref
Crossref
R. D. Arbeit, D. Maki, F. P. Tally, E. Campanaro & B. I. Eisenstein. (2004) The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections. Clinical Infectious Diseases 38:12, pages 1673-1681.
Crossref
Crossref
Christopher F. Carpenter & Henry F. Chambers. (2004) Daptomycin: Another Novel Agent for Treating Infections Due to Drug‐Resistant Gram‐Positive Pathogens. Clinical Infectious Diseases 38:7, pages 994-1000.
Crossref
Crossref
Peter J. Petersen, T. Z. Wang, Russell G. Dushin & Patricia A. Bradford. (2004) Comparative In Vitro Activities of AC98-6446, a Novel Semisynthetic Glycopeptide Derivative of the Natural Product Mannopeptimycin α, and Other Antimicrobial Agents against Gram-Positive Clinical Isolates. Antimicrobial Agents and Chemotherapy 48:3, pages 739-746.
Crossref
Crossref
Eric S Schweiger & Jeffrey M Weinberg. (2004) Novel antibacterial agents for skin and skin structure infections. Journal of the American Academy of Dermatology 50:3, pages 331-340.
Crossref
Crossref
James Siedlecki, Jason Hill, Ian Parr, Xiang Yu, Michael Morytko, Yanzhi Zhang, Jared Silverman, Nicole Controneo, Valerie Laganas, Tongchuan Li, Jianshi Li, Dennis Keith, George Shimer & John Finn. (2003) Array synthesis of novel lipodepsipeptide. Bioorganic & Medicinal Chemistry Letters 13:23, pages 4245-4249.
Crossref
Crossref
Jason Hill, James Siedlecki, Ian Parr, Michael Morytko, Xiang Yu, Yanzhi Zhang, Jared Silverman, Nicole Controneo, Valerie Laganas, Tongchuan Li, Jan-Ji Lai, Dennis Keith, George Shimer & John Finn. (2003) Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin. Bioorganic & Medicinal Chemistry Letters 13:23, pages 4187-4191.
Crossref
Crossref
Jeff Alder, Tongchaun Li, Donghui Yu, Larry Morton, Jared Silverman, Xi-Xian Zhang, Ian Critchley & Grace Thorne. (2003)
Analysis of Daptomycin Efficacy and Breakpoint Standards in a Murine Model of
Enterococcus faecalis
and
Enterococcus faecium
Renal Infection
. Antimicrobial Agents and Chemotherapy 47:11, pages 3561-3566.
Crossref
Crossref
Raymond Cha & Michael J. Rybak. (2003) Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagnostic Microbiology and Infectious Disease 47:3, pages 539-546.
Crossref
Crossref
Mario Cazzola, Alessandro Sanduzzi & Maria Gabriella Matera. (2003) Novelties in the field of antimicrobial compounds for the treatment of lower respiratory tract infections. Pulmonary Pharmacology & Therapeutics 16:3, pages 131-145.
Crossref
Crossref
George Sakoulas, George M. Eliopoulos, Jeff Alder & Claudie Thauvin- Eliopoulos. (2003)
Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant
Staphylococcus
aureus
. Antimicrobial Agents and Chemotherapy 47:5, pages 1714-1718.
Crossref
Crossref
Ian A. Critchley, Renée S. Blosser-Middleton, Mark E. Jones, Clyde Thornsberry, Daniel F. Sahm & James A. Karlowsky. (2003) Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001. Antimicrobial Agents and Chemotherapy 47:5, pages 1689-1693.
Crossref
Crossref
Barry H. Dvorchik, David Brazier, Michael F. DeBruin & Robert D. Arbeit. (2003) Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects. Antimicrobial Agents and Chemotherapy 47:4, pages 1318-1323.
Crossref
Crossref
Brunello Oliva, Keith Miller, Nico Caggiano, Alexander J. O'Neill, Gregory D. Cuny, Michael Z. Hoemann, James R. Hauske & Ian Chopra. (2003) Biological Properties of Novel Antistaphylococcal Quinoline-Indole Agents. Antimicrobial Agents and Chemotherapy 47:2, pages 458-466.
Crossref
Crossref
Karen M Wesson, Daniel S Lerner, Nanette B Silverberg & Jeffrey M Weinberg. (2003) Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Clinics in Dermatology 21:1, pages 64-70.
Crossref
Crossref
Richard H. Baltz. (2002) Combinatorial Glycosylation of Glycopeptide Antibiotics. Chemistry & Biology 9:12, pages 1268-1270.
Crossref
Crossref
Peter J. Petersen, Patricia A. Bradford, William J. Weiss, Timothy M. Murphy, P. E. Sum & Steven J. Projan. (2002)
In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate
Staphylococcus aureus
and Other Resistant Gram-Positive Pathogens
. Antimicrobial Agents and Chemotherapy 46:8, pages 2595-2601.
Crossref
Crossref
Mario Cazzola, Francesco Blasi, Stefano Centanni, Claudio Ferdinando Donner & Luigi Allegra. (2001) Advances in the Research and Development of Chemotherapeutic Agents for Respiratory Tract Bacterial Infections. Pulmonary Pharmacology & Therapeutics 14:5, pages 367-381.
Crossref
Crossref
Arthur L. Barry, Peter C. Fuchs & Steven D. Brown. (2001) In Vitro Activities of Daptomycin against 2,789 Clinical Isolates from 11 North American Medical Centers. Antimicrobial Agents and Chemotherapy 45:6, pages 1919-1922.
Crossref
Crossref
Jared A. Silverman, Nicole Oliver, Ted Andrew & Tongchuan Li. (2001) Resistance Studies with Daptomycin. Antimicrobial Agents and Chemotherapy 45:6, pages 1799-1802.
Crossref
Crossref
Maria Bodi, Carmen Ardanuy & Jordi Rello. (2001) Impact of Gram-positive resistance on outcome of nosocomial pneumonia. Critical Care Medicine 29:Supplement, pages N82-N86.
Crossref
Crossref
Arnold Louie, Pamela Kaw, Weiguo Liu, Nelson Jumbe, Michael H. Miller & George L. Drusano. (2001)
Pharmacodynamics of Daptomycin in a Murine Thigh Model of
Staphylococcus aureus
Infection
. Antimicrobial Agents and Chemotherapy 45:3, pages 845-851.
Crossref
Crossref
Santiago Grau, Mónica Marín, Francisco Álvarez-Lerma & Juan Luis Gimeno. (2001) Problemática y soluciones actuales en el tratamiento de las infecciones por microorganismos grampositivos. Enfermedades Infecciosas y Microbiología Clínica 19:8, pages 393-398.
Crossref
Crossref
F. B. OlesonJr.Jr., C. L. Berman, J. B. Kirkpatrick, K. S. Regan, J.-J. Lai & F. P. Tally. (2000) Once-Daily Dosing in Dogs Optimizes Daptomycin Safety. Antimicrobial Agents and Chemotherapy 44:11, pages 2948-2953.
Crossref
Crossref
Peter C. Fuchs, Arthur L. Barry & Steven D. Brown. (2000) Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagnostic Microbiology and Infectious Disease 38:1, pages 51-58.
Crossref
Crossref